VA106483 Dose Response in Females

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01171391
Recruitment Status : Completed
First Posted : July 28, 2010
Last Update Posted : December 1, 2010
Information provided by:
Vantia Ltd

July 19, 2010
July 28, 2010
December 1, 2010
July 2010
November 2010   (Final data collection date for primary outcome measure)
Pharmacokinetics [ Time Frame: 10 days ]
VA106483 plasma concentration pre-dose over a 24hr post-dose period to assess pharmacokinetics of each dose level
Same as current
Complete list of historical versions of study NCT01171391 on Archive Site
  • Pharmacodynamics [ Time Frame: 10 days ]
    Urine volume and osmolality
  • Safety and Tolerability [ Time Frame: 10 days ]
    AEs, laboratory safety tests, vital signs and ECG, physical examination.
Same as current
Not Provided
Not Provided
VA106483 Dose Response in Females
An Open Label, Dose Escalation Study to Assess Intra-Subject Dose Response to VA106483 in Female Subjects
The purpose of this study is to describe the pharmacokinetics and pharmacodynamics of VA106483 in female subjects.

Nocturia, defined as waking to void at least once per night between periods of sleep, is a common complaint and shows an age-dependent increase in both prevalence and severity (number of nocturnal voids). The most common causes are detrusor over-activity, reduced nighttime functional bladder capacity, and nocturnal polyuria.

VA106483 is a selective vasopressin V2-receptor agonist in development for nocturia. VA106483 is a non-peptide drug that displays much improved oral availability over desmopressin and low dependence on glomerular filtration for its elimination.

VA106483 has been administered to 184 subjects (including healthy adult subjects [males and females], children [males and females] with nocturia and 48 elderly males [aged 65 years and over]). It has been administered as single doses both intravenously, up to doses of approximately 250 mg and orally up to 50 mg It is also being investigated in approximately 123 male subjects (two-thirds on active medication, one third on placebo) with nocturia in a current study with dosing for up to 8 weeks.

This intra-subject dose escalation study has previously been conducted in 10 elderly male subjects to determine whether subjects demonstrated a dose-dependent pharmacokinetic and pharmacodynamic (urine osmolality and diuresis) response and whether the dose of VA106483 could be titrated within an individual patient to achieve optimal clinical response in clinical practice. Given that to date, only 8 females have been exposed to VA106483, the purpose of this study is to confirm that the described duration of pharmacokinetics and pharmacodynamics of VA106483 in males is similar in females.

Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Drug: VA106483
    1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
  • Other: Placebo
    Placebo on Day 1
  • Experimental: VA106483 1mg
    Intervention: Drug: VA106483
  • Experimental: VA106483 2mg
    Intervention: Drug: VA106483
  • Experimental: VA106483 4mg
    Intervention: Drug: VA106483
  • Placebo Comparator: Sugar pill
    Intervention: Other: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
November 2010
November 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female subjects 40 years and above
  • BMI 18 to 32 kg/m2
  • Using adequate contraception and providing negative pregnancy tests pre-dose
  • In good health as determined by medical history and screening tests
  • Subject is willing and able to abstain from alcohol and caffeine-containing food and beverages 72 hours prior to dosing and throughout the study
  • Provide written, informed consent

Exclusion Criteria:

  • Pregnancy or lactation
  • Evidence of serious pathology or diseases including heart, hormone, liver and kidney, psychiatric and neurological problems, including syndrome of inappropriate antidiuretic hormone secretion, polydipsia or diabetes insipidus
  • Likely to be hypersensitive to VA106483
  • History of any relevant allergy
  • Participation in a clinical study within 30 days
  • Donation of blood (500 mL) within 60 days prior to dosing
  • A history of alcohol abuse or drug addiction
  • Positive results for HIV, HBV or HCV or drugs of abuse
  • Currently taking any diuretics or clinically significant cytochrome 3A4 inhibitors or inducers
  • Use of any non-prescription preparation within 72 hours prior to dosing, with the exception of ibuprofen, and acetaminophen used at recommended doses
  • Treatment within the previous 3 months of drugs known to have a well defined potential for hepatoxicity
  • Current smokers or recent ex-smokers
  • Other protocol defined eligibility criteria may apply
Sexes Eligible for Study: Female
40 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Chief Medical Officer, Vantia Ltd
Vantia Ltd
Not Provided
Principal Investigator: Ralph Schutz Quintiles Phase I Services
Vantia Ltd
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP